Last Updated: July 2026
Published by: Saif Pharma — a specialist oncology medicine supplier serving patients, pharmacies, and distributors worldwide.
Medical Review: Reviewed by Dr. Nusrat Jahan, MBBS, MD (Medical Oncology)
Content Basis: This article is based on official prescribing information, product monographs, and regulatory product documentation from SFDA and DGDA (Directorate General of Drug Administration, Bangladesh).
Sources: medlineplus.gov, mayoclinic.org, accessdata.fda.gov, accessdata.fda.gov, accessdata.fda.gov, drugs.com, beaconmedicare.com.bd

Key Takeaways
- Hydroxyurea is an oral antimetabolite approved for three indications: chronic myelogenous leukemia (CML), head and neck cancer, and sickle cell anemia in adults and children aged 2 years and older.
- It works by inhibiting ribonucleotide reductase to block DNA synthesis in cancer cells, and by reducing the formation of sickle-shaped red blood cells in patients with sickle cell anemia — giving it clinical utility across both oncology and hematology.
- Hydroxyurea is unambiguously considered a form of chemotherapy and must be administered only under the supervision of qualified clinicians experienced in cytotoxic therapy.
- The drug carries a boxed warning covering severe myelosuppression and malignancies (including secondary malignancies), with additional warnings and precautions for embryo-fetal toxicity; breastfeeding must be discontinued during treatment.
- Three Bangladeshi-manufactured brands — Hydrea, Hydronix, and Mylostat — are available across multiple capsule strengths, tablet strengths, and oral solution, supporting both adult and pediatric use.
- Procurement teams in Saudi Arabia must verify SFDA registration and compliance status for each brand before placing orders; all brands supplied through our chain are exclusively manufactured in Bangladesh.
What Is Hydroxyurea and What Is It Used For?
Hydroxyurea is an oral antimetabolite agent used in the treatment of several serious hematologic and oncologic conditions. It belongs to the therapeutic class of antimetabolites and works at the cellular level to interfere with abnormal cell proliferation and red blood cell sickling.
Hydroxyurea is FDA-approved for the following indications:
- Chronic myelogenous leukemia (CML) — a primary oncologic indication for which hydroxyurea has been used clinically for decades, with documented efficacy in reducing elevated white blood cell counts
- Head and neck cancer — including cancers of the mouth, cheek, tongue, throat, tonsils, and sinuses, where it serves as part of multimodal treatment protocols
- Sickle cell anemia — approved for use in adults and children 2 years of age and older, representing a significant advancement in disease-modifying therapy for this inherited blood disorder
The sickle cell anemia indication carries age restrictions that vary by formulation: Siklos (hydroxyurea tablet) is approved for patients aged 2 years and older, while Xromi (hydroxyurea oral solution) is approved for patients aged 6 years and older, both based on clinical trial data demonstrating safety and efficacy in pediatric populations. For the cancer indications — CML and head and neck cancer — no specific minimum age restriction is detailed in the current prescribing sources, though treatment decisions are individualized based on patient factors and disease characteristics.
Hydroxyurea uses span both oncology and hematology, making it a clinically versatile agent that is in demand across hospital formularies, specialty pharmacies, and oncology centers. According to World Health Organization Essential Medicines List guidelines, hydroxyurea represents a critical therapeutic option for resource-limited settings treating sickle cell disease. Procurement teams sourcing hydroxyurea 500 mg capsules or other strengths for Saudi Arabian healthcare facilities will find this drug available under multiple Bangladeshi-manufactured brands.
Mechanism of Action: How Hydroxyurea Works
Hydroxyurea is classified as a chemotherapy antimetabolite agent. It exerts its primary anticancer effect by acting as a ribonucleotide reductase inhibitor, causing an immediate inhibition of DNA synthesis. By blocking this enzyme, hydroxyurea prevents cancer cells from replicating their DNA, thereby halting cell division. This mechanism is the basis for its use in CML and head and neck cancer.
In the context of sickle cell disease, hydroxyurea works through a distinct but related pathway. Research published in the New England Journal of Medicine demonstrates that it helps prevent the formation of sickle-shaped red blood cells — the abnormally rigid, crescent-shaped cells responsible for vaso-occlusive crises and organ damage. The drug increases fetal hemoglobin (HbF) production, which inhibits the polymerization of sickle hemoglobin. By reducing the proportion of these deformed cells in circulation, hydroxyurea significantly decreases the frequency and severity of sickle cell complications.
Clinical Evidence Supporting Mechanism
The Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), a landmark randomized controlled trial, established that hydroxyurea substantially reduces the frequency of painful crises in adults with sickle cell disease (median crisis rate reduced from approximately 4.5 to 2.5 per year, roughly a 44% reduction). Subsequent pediatric studies, including the BABY HUG trial published in The Lancet, confirmed similar benefits in children as young as 9 months, though regulatory approval extends to age 2 and older.
Because hydroxyurea directly interferes with DNA synthesis, it is unambiguously considered a form of chemotherapy. Healthcare providers and procurement professionals should treat it accordingly, with full awareness of its cytotoxic profile. Its dual mechanism — anti-proliferative in cancer and anti-sickling in hematology — explains its broad clinical utility across two distinct disease categories. For further context on chemotherapy evolution and cutting-edge cancer treatment techniques, additional clinical resources are available.
Hydroxyurea in Chronic Myelogenous Leukemia (CML)
Chronic myelogenous leukemia (CML) is one of the primary approved indications for hydroxyurea, and it has been used in CML management since the drug’s original FDA approval in — representing over five decades of clinical experience. In the oncology setting, hydroxyurea is employed as a cytotoxic therapy to reduce the elevated white blood cell counts characteristic of CML and to help control disease burden.
Clinical Practice Considerations
While tyrosine kinase inhibitors (TKIs) such as imatinib have become first-line therapy for CML since the early 2000s, hydroxyurea maintains an important role in specific clinical scenarios. According to National Comprehensive Cancer Network (NCCN) guidelines, hydroxyurea may be used for rapid cytoreduction in patients presenting with hyperleukocytosis, as a bridge to definitive therapy, or in resource-limited settings where TKIs are unavailable.
Given its cytotoxic mechanism, hydroxyurea for CML must be administered only under the supervision of qualified clinicians who are experienced in the use of cytotoxic therapy. This requirement is not merely a precaution — it reflects the drug’s narrow therapeutic window and the complexity of managing myelosuppression in an already immunocompromised patient population. Hematology-oncology specialists typically oversee treatment protocols, with regular monitoring of complete blood counts and clinical response parameters.
Important Safety Information: Clinicians and hospital procurement teams should be aware that hydroxyurea carries boxed warnings relevant to its use in CML, including the risk of severe myelosuppression and secondary malignancies. Hydroxyurea is also recognized as a carcinogenic agent by the International Agency for Research on Cancer (IARC), which must be factored into long-term treatment planning and patient counseling. These risks underscore the importance of institutional protocols and specialist oversight when this drug is included in a hospital formulary or oncology treatment program.
Available Forms and Strengths
Hydroxyurea is available in multiple oral dosage forms and strengths, providing flexibility for clinical use across different patient populations and indications. The following forms are available across the Bangladeshi-manufactured brands — Hydrea, Hydronix, and Mylostat — that we supply:
| Dosage Form | Available Strengths | Clinical Application |
|---|---|---|
| Capsules | 50 mg, 100 mg, 250 mg, 500 mg | Flexible dosing for adults and children; 500 mg most common for adult oncology |
| Tablets | 100 mg, 1000 mg | Alternative solid dosage form; 1000 mg for high-dose protocols |
| Oral solution | Liquid formulation | Pediatric use and patients with swallowing difficulties |
Pediatric Formulation Considerations
The availability of an oral solution alongside capsule and tablet formulations supports use across adult and pediatric populations, including children aged 2 years and older for the sickle cell anemia indication. According to American Society of Hematology guidelines, liquid formulations facilitate accurate weight-based dosing in pediatric patients, where dose adjustments of 5-10 mg/kg/day are common during titration phases.
Specific dosing regimens, including strength selection and administration frequency, are determined exclusively by the treating physician in accordance with the official prescribing information. Procurement teams should confirm which strengths are required when placing orders, as institutional formularies may stock different strengths based on their patient population mix and predominant indications.
Safety Profile and Important Warnings
Hydroxyurea is a highly toxic drug with a low therapeutic index and the potential for severe, sometimes life-threatening or fatal adverse effects. It must be administered only under the supervision of qualified clinicians experienced in cytotoxic therapy. The following safety information is essential for healthcare providers, pharmacists, and procurement professionals handling this agent.
Boxed Warnings
- Myelosuppression: Severe decreases in blood cell counts can increase the risk of serious infection or bleeding. Complete blood count monitoring is required before and during therapy, with dose modifications based on hematologic parameters as outlined in prescribing information.
- Malignancies: Secondary malignancies, including leukemia and skin cancers, have been associated with hydroxyurea use. Long-term surveillance is recommended, particularly in patients with extended treatment duration.
- Carcinogenicity: Hydroxyurea is recognized as a carcinogenic agent based on animal studies and human epidemiological data. The National Toxicology Program classifies it as reasonably anticipated to be a human carcinogen.
- Embryo-fetal toxicity: Hydroxyurea can cause fetal harm when administered to pregnant individuals. Pregnancy testing, contraception counseling, and risk communication are mandatory components of treatment initiation. Patients of reproductive potential must use effective contraception during treatment and for at least 6 months after the final dose.
Common Adverse Reactions
The most frequently reported adverse reactions are hematological, gastrointestinal, and related to general well-being. Clinical trial data and post-marketing surveillance have identified the following common reactions (occurring in ≥10% of patients):
- Hematologic: Neutropenia, thrombocytopenia, anemia (dose-dependent and reversible)
- Gastrointestinal: Nausea, vomiting, anorexia, loss of appetite, diarrhea, constipation, mucositis
- Constitutional: Fever, chills, excessive tiredness or weakness, malaise
- Dermatologic: Hives or skin rash, hyperpigmentation, nail changes, alopecia
- Musculoskeletal: Joint stiffness or swelling
- Neurologic: Numbness or tingling of the fingers or toes (peripheral neuropathy)
- Infectious: Sore throat, increased susceptibility to infections
- Hemorrhagic: Unusual bleeding or bruising
Serious Adverse Effects
Serious adverse effects requiring immediate medical attention include:
- Severe myelosuppression — potentially life-threatening bone marrow suppression
- Serious infection — including opportunistic infections in immunocompromised patients
- Severe bleeding — hemorrhagic complications secondary to thrombocytopenia
- Gastrointestinal bleeding — bloody or black tarry stools, vomiting blood
- Vasculitic toxicities — including vasculitic ulcerations and gangrene, particularly in patients with sickle cell disease
- Cutaneous vasculitic toxicities — leg ulcers, requiring treatment interruption
- Hepatotoxicity — elevated liver enzymes, hepatic dysfunction
- Pulmonary toxicity — interstitial pneumonitis, pulmonary fibrosis (rare)
- Secondary malignancies — increased risk with prolonged exposure
- Embryo-fetal toxicity — teratogenic effects documented in animal studies
Healthcare providers should refer to the FDA Adverse Event Reporting System (FAERS) for updated safety information and post-marketing surveillance data.
Lactation Guidance
Contraindication in Breastfeeding: Hydroxyurea is excreted in human milk. Due to the potential for serious adverse reactions in breastfed infants, including myelosuppression and carcinogenicity, breastfeeding must be discontinued during treatment with hydroxyurea. Women should not resume breastfeeding until cleared by their healthcare provider, typically not until after drug elimination is complete.
Required Monitoring Parameters
Clinical practice standards require the following monitoring schedule:
- Complete blood count (CBC): Baseline, weekly during dose titration, then every 2-4 weeks during maintenance
- Renal function: Baseline and periodically (dose adjustment required in renal impairment)
- Hepatic function: Baseline and periodically
- Pregnancy testing: Before treatment initiation in individuals of reproductive potential
- Skin examination: Regular surveillance for secondary skin malignancies
Bangladeshi Brands We Supply: Hydrea, Hydronix, and Mylostat
We source and supply three Bangladeshi-manufactured hydroxyurea brands for export to Saudi Arabia and the broader Middle East region. All brands are manufactured in Bangladesh and are the exclusive focus of our supply chain — we do not source or distribute brands manufactured outside Bangladesh. Our direct relationships with Bangladeshi manufacturers enable consistent supply, quality assurance, and competitive pricing for institutional buyers.
Hydrea
Hydrea is manufactured by Everest Pharmaceuticals Ltd. (Bangladesh). Everest Pharmaceuticals is a WHO-GMP certified manufacturer with over two decades of experience in oncology and specialty pharmaceutical production. It is available in capsule and tablet forms across multiple strengths, making it suitable for both oncology and sickle cell anemia indications.
Hydronix
Hydronix is manufactured by Beacon Pharmaceuticals PLC (Bangladesh). Beacon Pharmaceuticals is a well-established Bangladeshi manufacturer with a track record in oncology and specialty pharmaceutical production. The company holds multiple international regulatory approvals and exports to over 40 countries globally, demonstrating manufacturing quality standards that meet international requirements.
Mylostat
Mylostat is manufactured by Drug International Ltd. (Bangladesh). Drug International is one of Bangladesh’s leading pharmaceutical manufacturers, with extensive experience in cytotoxic and specialty drug production. This brand provides an additional sourcing option for procurement teams requiring consistent supply of hydroxyurea across multiple dosage forms.
Global Market Reference
For global market context, the originator brand Droxia (manufactured by Bristol-Myers Squibb) has historically been a reference product in international markets, particularly for the sickle cell anemia indication. However, the Bangladeshi-manufactured brands listed above represent the products available through our supply chain and offer cost-effective alternatives with equivalent active pharmaceutical ingredient specifications. Procurement teams in Saudi Arabia can rely on these brands as their primary sourcing options for hydroxyurea, with the assurance that all products meet Bangladeshi regulatory manufacturing standards.
Manufacturing Standards
All three brands are manufactured in facilities that comply with Good Manufacturing Practice (GMP) standards as required by the Directorate General of Drug Administration (DGDA) of Bangladesh. Many Bangladeshi pharmaceutical manufacturers also hold WHO-GMP prequalification or have passed inspections by international regulatory authorities, supporting their export credentials.
Regulatory Compliance for the Saudi Arabian Market
Pharmaceutical imports into Saudi Arabia are regulated by the Saudi Food and Drug Authority (SFDA), accessible at sfda.gov.sa. The SFDA oversees the registration, importation, and distribution of all pharmaceutical products within the Kingdom. Any importer, distributor, or healthcare institution procuring hydroxyurea for use in Saudi Arabia must verify that the specific brand and product presentation meets current SFDA registration and compliance requirements prior to procurement.
SFDA Registration Requirements
The SFDA registration process for imported pharmaceuticals typically requires:
- Certificate of Pharmaceutical Product (CPP) from the country of manufacture
- Good Manufacturing Practice (GMP) certification for the manufacturing facility
- Product dossier including quality, safety, and efficacy data
- Stability studies conducted under ICH guidelines
- Certificate of Analysis (CoA) for each batch imported
- Halal certification where applicable for capsule shells and excipients
Importers should consult the SFDA Drug Sector guidelines for current requirements and submission procedures.
From a global regulatory standpoint, hydroxyurea has a well-established regulatory history, having received its initial FDA approval in — one of the longer-standing approvals in oncology and hematology pharmacotherapy. The drug was initially approved for CML and later received expanded indications for head and neck cancer and sickle cell anemia (the latter approved in following the landmark MSH trial results). This regulatory foundation supports its recognized clinical standing internationally and facilitates registration processes in markets that reference FDA or EMA approvals.
Importer Due Diligence
Saudi Arabian importers are advised to work with their regulatory affairs teams and consult the SFDA’s official product registration database to confirm the compliance status of each brand before placing bulk orders. The SFDA maintains an online searchable database of registered products, which should be the primary reference for verification. Additionally, importers should:
- Verify that the manufacturer holds current GMP certification recognized by SFDA
- Confirm that the specific product strength and presentation are registered
- Ensure proper cold chain management if required (though hydroxyurea typically requires standard storage conditions)
- Maintain documentation for customs clearance and SFDA inspection
- Establish pharmacovigilance reporting mechanisms as required by SFDA regulations
GCC Regulatory Harmonization
Saudi Arabia participates in the Gulf Cooperation Council (GCC) pharmaceutical regulatory harmonization initiative, which aims to streamline registration processes across member states. Products registered in one GCC country may benefit from expedited review in others, though country-specific requirements still apply. Procurement teams operating across multiple GCC markets should consider this when planning regional supply strategies.
Why Source Hydroxyurea from a Bangladeshi B2B Supplier?
As a Bangladeshi pharmaceutical B2B exporter with specialized expertise in oncology and hematology products, we offer direct access to manufacturer-level sourcing for hydroxyurea brands produced in Bangladesh. This direct supply chain model reduces intermediary layers, supports consistent product availability, and enables reliable fulfillment for bulk and repeat orders destined for Saudi Arabia and the wider Middle East.
Key Supply Chain Advantages
- Direct manufacturer relationships: We maintain established partnerships with Everest Pharmaceuticals, Beacon Pharmaceuticals, and Drug International, ensuring priority allocation and competitive pricing
- Quality assurance: All products sourced from WHO-GMP certified or nationally regulated facilities with documented quality management systems
- Regulatory support: We provide complete export documentation including Certificates of Pharmaceutical Product, GMP certificates, and batch-specific Certificates of Analysis
- Flexible order quantities: Capable of fulfilling both container-load and smaller institutional orders based on procurement requirements
- Reliable lead times: Established logistics networks enable predictable delivery schedules to Saudi Arabian ports
- Technical expertise: Our team includes pharmaceutical professionals who understand oncology and hematology product requirements
Comprehensive Product Range
Our sourcing portfolio — Hydrea, Hydronix, and Mylostat — covers the full range of available dosage forms, including 50 mg, 100 mg, 250 mg, and 500 mg capsules, 100 mg and 1000 mg tablets, and oral solution. This breadth of product availability makes us a practical single-source partner for hospital procurement teams, specialty pharmacies, and pharmaceutical distributors operating in Saudi Arabia.
Whether your facility requires hydroxyurea for:
- CML treatment protocols in hematology-oncology departments
- Head and neck cancer programs as part of multimodal therapy
- Sickle cell anemia management in both adult and pediatric populations
…we are equipped to support your procurement requirements at scale.
Bangladesh Pharmaceutical Manufacturing Excellence
Bangladesh has emerged as a significant player in global pharmaceutical manufacturing, with the industry supplying over 150 countries worldwide. The country benefits from:
- TRIPS agreement exemptions allowing production of generic medicines until 2033
- Cost-competitive manufacturing infrastructure
- Skilled pharmaceutical workforce with technical expertise
- Increasing number of WHO-GMP prequalified facilities
- Government support for pharmaceutical exports through policy incentives
These factors position Bangladeshi manufacturers as reliable long-term partners for international procurement, particularly for essential oncology and hematology medicines like hydroxyurea.
We export exclusively Bangladeshi-manufactured brands, ensuring supply chain transparency and brand consistency. Our commitment to single-origin sourcing eliminates confusion about product provenance and simplifies regulatory compliance for importers. Contact us to discuss product availability, brand options, and export logistics to Saudi Arabia.
How to Inquire About Hydroxyurea Supply
B2B buyers in Saudi Arabia — including hospital procurement officers, pharmaceutical distributors, and specialty pharmacy managers — are invited to contact us directly for product availability, brand options, and export pricing for hydroxyurea.
What to Include in Your Inquiry
To expedite your quote request, please provide:
- Specific product requirements: Brand preference (Hydrea, Hydronix, or Mylostat), dosage form, and strength
- Order quantity: Number of units or packs required
- Delivery destination: Port or city in Saudi Arabia
- Regulatory status: Whether SFDA registration is already in place or assistance is needed
- Delivery timeline: Urgency and preferred delivery schedule
- Organization details: Company name, license information, and contact person
We supply the following Bangladeshi-manufactured brands: Hydrea (Everest Pharmaceuticals Ltd.), Hydronix (Beacon Pharmaceuticals PLC), and Mylostat (Drug International Ltd.), available in multiple strengths and dosage forms for export to Saudi Arabia.
Our Service Commitment
- Rapid response: Initial quote provided within 24-48 hours of inquiry
- Transparent pricing: Clear breakdown of product cost, shipping, and documentation fees
- Documentation support: Complete export documentation package including CPP, GMP certificates, and CoA
- Logistics coordination: Assistance with freight forwarding, customs clearance, and delivery tracking
- Post-delivery support: Ongoing customer service for repeat orders and supply chain optimization
Contact us for availability and pricing. Our team is ready to support your procurement needs with reliable sourcing, competitive lead times, and full export documentation for the Saudi Arabian market. We understand the critical nature of oncology and hematology drug supply and prioritize consistent availability for our institutional partners.
Frequently Asked Questions
What is hydroxyurea used for?
Hydroxyurea is used to treat chronic myelogenous leukemia (CML), head and neck cancers (including cancers of the mouth, tongue, throat, tonsils, and sinuses), and sickle cell anemia in adults and children aged 2 years and older. Its dual utility across oncology and hematology makes it a clinically versatile agent stocked across hospital formularies and specialty pharmacies.
For CML, hydroxyurea serves as a cytoreductive agent, particularly useful for managing hyperleukocytosis or as bridge therapy. In head and neck cancer, it may be used as part of combination regimens. For sickle cell disease, it represents the first FDA-approved disease-modifying therapy, reducing painful crises and improving quality of life. Clinical guidelines from the American Society of Hematology recommend hydroxyurea as first-line therapy for most patients with sickle cell disease.
Is hydroxyurea considered chemotherapy?
Yes, hydroxyurea is unambiguously considered a form of chemotherapy — it is classified as an antimetabolite and works by directly interfering with DNA synthesis to halt cancer cell division. Because of its cytotoxic profile, it must be administered only under the supervision of qualified clinicians experienced in cytotoxic therapy.
The drug’s classification as chemotherapy applies even when used for non-cancer indications such as sickle cell disease. Healthcare providers must implement appropriate handling precautions consistent with cytotoxic drug protocols, including use of personal protective equipment during preparation and administration. The NIOSH Hazardous Drug List includes hydroxyurea, requiring special handling procedures in healthcare settings.
How does hydroxyurea work in sickle cell disease?
In sickle cell anemia, hydroxyurea helps prevent the formation of the abnormally rigid, crescent-shaped red blood cells responsible for vaso-occlusive crises and organ damage, thereby reducing the frequency and severity of complications. This anti-sickling effect is distinct from its DNA-synthesis-blocking mechanism used in cancer treatment, but both actions stem from its activity as a ribonucleotide reductase inhibitor.
The primary mechanism involves increasing fetal hemoglobin (HbF) production. Fetal hemoglobin does not participate in the polymerization process that causes red blood cells to sickle. By elevating HbF levels from typical adult levels of <1% to 15-20% or higher, hydroxyurea significantly reduces sickling events. Additional beneficial effects include improved red blood cell hydration, reduced white blood cell counts (decreasing inflammation), and improved nitric oxide bioavailability (enhancing vascular function). These multiple mechanisms contribute to reduced hospitalization rates, decreased need for blood transfusions, and improved survival in patients with sickle cell disease.
What are the most important side effects of hydroxyurea patients should know about?
Common side effects include nausea, vomiting, and unusual bleeding or bruising, along with fever, chills, excessive tiredness, and numbness or tingling of the fingers or toes; serious risks include severe myelosuppression, vasculitic ulcerations and gangrene, and embryo-fetal toxicity. Breastfeeding must also be discontinued during treatment because hydroxyurea is excreted in human milk.
Patients should seek immediate medical attention if they experience:
- Signs of infection (fever, chills, persistent sore throat)
- Unusual bleeding or bruising
- Black, tarry stools or blood in urine
- Severe skin reactions or leg ulcers
- Severe fatigue or weakness
- Yellowing of skin or eyes (jaundice)
Regular blood count monitoring is essential to detect myelosuppression early. Most side effects are dose-dependent and reversible with dose adjustment or temporary treatment interruption. Patient education materials from organizations like the Sickle Cell Disease Association of America provide comprehensive information for patients starting hydroxyurea therapy.
Which hydroxyurea brands do you supply for export to Saudi Arabia?
We supply three Bangladeshi-manufactured hydroxyurea brands — Hydrea (by Everest Pharmaceuticals Ltd.), Hydronix (by Beacon Pharmaceuticals PLC), and Mylostat (by Drug International Ltd.) — all available in multiple capsule strengths, tablet strengths, and oral solution for export to Saudi Arabia. We exclusively source brands manufactured in Bangladesh and do not distribute brands produced outside Bangladesh.
Available strengths across our brand portfolio:
- Capsules: 50 mg, 100 mg, 250 mg, 500 mg
- Tablets: 100 mg, 1000 mg
- Oral solution: Liquid formulation for pediatric use
All three manufacturers maintain GMP-certified facilities and can provide complete regulatory documentation for SFDA registration. We can assist with brand selection based on your specific requirements, including pricing considerations, packaging preferences, and regulatory status. Our direct manufacturer relationships ensure consistent supply and competitive pricing for institutional buyers.
What should procurement teams in Saudi Arabia verify before ordering hydroxyurea?
Procurement teams must confirm that the specific brand and product presentation meets current Saudi Food and Drug Authority (SFDA) registration and compliance requirements before placing bulk orders. It is recommended to consult the SFDA’s official product registration database and work with your regulatory affairs team to validate each brand’s compliance status prior to procurement.
Essential verification steps include:
- SFDA registration status: Verify the specific brand, strength, and presentation are registered in the SFDA database
- Manufacturer GMP certification: Confirm the manufacturing facility holds current GMP certification recognized by SFDA
- Import license validity: Ensure your organization’s pharmaceutical import license is current
- Storage requirements: Verify your facility can meet storage conditions (typically 15-30°C for hydroxyurea)
- Shelf life considerations: Confirm remaining shelf life meets your institution’s minimum acceptance criteria (typically 18-24 months)
- Documentation requirements: Ensure supplier can provide Certificate of Pharmaceutical Product, GMP certificate, and batch-specific Certificate of Analysis
- Pharmacovigilance setup: Establish adverse event reporting mechanisms as required by SFDA
We provide comprehensive support throughout the verification and procurement process, including assistance with SFDA registration if needed. Our regulatory affairs team can coordinate with your compliance department to ensure all requirements are met before shipment.
- 1. medlineplus.gov
- 2. www.mayoclinic.org
- 3. www.accessdata.fda.gov
- 4. www.accessdata.fda.gov
- 5. www.accessdata.fda.gov
- 6. www.drugs.com
- 7. www.beaconmedicare.com.bd
Access This Medicine Through Saif Pharma
We are a specialist oncology medicine supplier delivering to patients, pharmacies, hospitals, and distributors worldwide. Contact us for availability and sourcing support.
We do not publish prices online. All pricing is provided directly by our specialist supply team on request.
Medical Information Notice: This content is for informational purposes only and is based on official pharmaceutical product documentation. It does not constitute medical advice. Patients should consult their doctor or pharmacist before taking any medication.
Regulatory Disclaimer: Sourcing and distribution are subject to regional import regulations, quotas, and verified medical prescriptions where applicable. Pricing and availability are subject to change without notice.
Content Currency: This article was last reviewed and updated in July 2026. Regulatory approval statuses and product availability are subject to change; readers are advised to consult official regulatory databases for the most current information.